Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma

BACKGROUND: Autologous stem cell transplantation (ASCT) is the standard treatment for refractory/relapsed B cell non-Hodgkin’s lymphoma (R/R B-NHL), whereas chimeric antigen receptor T (CAR-T) therapy targeting CD19 is emerging as an alternative strategy. Here, we report a comparative analysis of th...

詳細記述

保存先:
書誌詳細
出版年:JCI Insight
主要な著者: Li, Caixia, Zhang, Ying, Zhang, Changfeng, Chen, Jia, Lou, Xiaoyan, Chen, Xiaochen, Kang, Liqing, Xu, Nan, Li, Minghao, Tan, Jingwen, Sun, Xiuli, Zhou, Jin, Yang, Zhen, Zong, Xiangping, Wang, Pu, Xu, Ting, Qu, Changju, Huang, Haiwen, Jin, Zhengming, Yu, Lei, Wu, Depei
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2019
主題:
Clinical Medicine
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777912/
https://ncbi.nlm.nih.gov/pubmed/31335321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.130195
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料